Molecular targets of indirubins

International Journal of Clinical Pharmacology and Therapeutics

Volumn 43, Issue 12, 2005, Pages 592-594

  Jakobs, S ^a   Merz, K H ^a   Vatter, S ^a   Eisenbrand, G ^a  

^a University of Koblenz Landau   (Germany)

Author keywords

c Src; CDK inhibition; GSK 3 ; Indirubins; Retinoblastoma protein (pRb); Stat3; VEGFR 2 KDR

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN A; CYCLIN B; CYCLIN D; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; E 671; E 729; E 804; INDIRUBIN; PROTEIN KINASE; PROTEIN MCL 1; RETINOBLASTOMA PROTEIN; STAT3 PROTEIN; SURVIVIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; DRUG BINDING SITE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 29444451748     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP43592     Document Type: Article

References (8)

1. Eisenbrand G, Hippe F, Jakobs S, Muehlbeyer S 2004 Molecular mechanisms of indirubin and its derivatives, novel anticancer molecules with origin in traditional Chinese phytomedicine. J Cancer Res Clin Oncol 130: 627-635
2. Fiebig H, Marko D, Eisenbrand G 2001 Indirubins, novel potent inhibitors of cyclin-dependent kinases, inhibit the growth of human xenograft tumours. Proc Am Ass Cancer Res 42: 2458
3. Hoessel R, Leclerc S, Endicott JA, Nobel MEM, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, Niederbeger E, Tang W, Eisenbrand G, Meijer L 1999 Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1: 60-67
4. Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, Greengard P, Biernat J, Wu YZ, Mandelkow EM, Eisenbrand G, Meijer L 2001 Indirubins inhibit glycogen synthase kinase-3β and CDK5/p25, two-protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease - a property common to most CDK inhibitors? J Biol Chem 276: 251-260
5. Marko D, Schaetzle S, Friedel A, Niederberger E, Genzlinger A, Zankl H, Meijer L, Eisenbrand GI 2001 Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br J Cancer 84: 283-289
6. Nam S, Buettner R, Turkson J, Kim D, Cheng JQ, Muehlbeyer S, Hippe F, Vatter S, Merz KH, Eisenbrand G, Jove R 2005 Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. PNAS 102: 5998-6003
7. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR 1990 New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112
8. Siemeister G, Thierauch KH, Prien O, Jautelat R, Eisenbrand G 2002 Utilization of selective indirubin derivatives as VEGF-R inhibitors. WO 02/092079 A1